China National Accord Medicines Corporation Ltd. (000028.SZ), a subsidiary of SINOPHARM (01099), announced preliminary financial results for the three months ended March 31, 2026. The company reported operating revenue of 17.823 billion yuan, representing a decrease of 2.57% compared to the same period last year. Net profit attributable to shareholders of the listed company was 287 million yuan, down 12.36% year-on-year. Basic earnings per share stood at 0.52 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.